Cite

    Michael Morse et al.. “Novel adenoviral serotype 5 based immunotherapeutic induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients.” Journal for immunotherapy of cancer, vol. 1, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100135177904.0x000004